Cue Biopharma (CUE) Cash from Investing Activities (2017 - 2025)
Cue Biopharma (CUE) posted Cash from Investing Activities of $7.0 million for Q4 2025, up 203.72% sequentially from -$6.8 million in Q3 2025, and up 702100.0% YoY from N/an in Q4 2024.
Cue Biopharma (CUE) Cash from Investing Activities (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Cash from Investing Activities for 9 years, with the latest figure at $7.0 million in Q4 2025.
- Quarterly Cash from Investing Activities rose 702100.0% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75000.0 (up 134.38% YoY) and the FY2025 annual result came in at $75000.0, up 134.38% from the prior year.
- Cash from Investing Activities grew to $7.0 million in Q4 2025 per CUE's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $15.0 million in Q1 2023 and troughed at -$29.5 million in Q3 2022.
- A 5-year average of $505658.5 and a median of -$10000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 978177.89% in 2022, down 268263.64% in 2022.
- Over 5 years, Cash from Investing Activities stood at $511.0 in 2021, then jumped by 978177.89% to $5.0 million in 2022, then gained by 0.02% to $5.0 million in 2023, then slumped by 100.02% to -$1000.0 in 2024, then surged by 702100.0% to $7.0 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $7.0 million, -$6.8 million, and -$27000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.02 Mn |
| Dec 31, 2025 | 7.02 Mn |
| Sep 30, 2025 | -6.77 Mn |
| Sep 30, 2025 | -6.77 Mn |
| Jun 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -55,000.00 |
| Mar 31, 2024 | -55,000.00 |
| Sep 30, 2023 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 5.00 Mn |